期刊
MOLECULAR THERAPY
卷 28, 期 7, 页码 1569-1584出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2020.04.018
关键词
-
资金
- NIH [R01AI146101-01, 5P01AI097092-07]
- National Institute of Allergy and Infectious Disease (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
- US Public Health Service [AI07647]
- BioNTech RNA Pharmaceuticals
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2019/01523-3]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [19/01523-3] Funding Source: FAPESP
Influenza viruses are respiratory pathogens of public health concern worldwide with up to 650,000 deaths occurring each year. Seasonal influenza virus vaccines are employed to prevent disease, but with limited effectiveness. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence. In this study, we have utilized lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccines to intradermally deliver a combination of conserved influenza virus antigens (hemagglutinin stalk, neuraminidase, matrix-2 ion channel, and nucleoprotein) and induce strong immune responses with substantial breadth and potency in a murine model. The immunity conferred by nucleoside-modified mRNA-lipid nanoparticle vaccines provided protection from challenge with pandemic H1N1 virus at 500 times the median lethal dose after administration of a single immunization, and the combination vaccine protected from morbidity at a dose of 50 ng per antigen. The broad protective potential of a single dose of combination vaccine was confirmed by challenge with a panel of group 1 influenza A viruses. These findings support the advancement of nucleoside-modified mRNA-lipid nanoparticle vaccines expressing multiple conserved antigens as universal influenza virus vaccine candidates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据